Sign up USA
Proactive Investors - Run By Investors For Investors

Proactive Investors One2One Investor Forum - London

Clinigen Group PLC | Redx Pharma Plc | MaxCyte | Abzena plc

The presentations will start at 6:00pm and finish at approx 8:00pm. After the presentations are complete the directors will also be available to take questions during a free canapé and wine reception. Details on the presenting companies can be found below.

 

This event is suitable for the following:

Sophisticated & private investors, private client brokers, fund managers, financial institutions, hedge funds, buy & sell side analysts and journalists.

 

The event is not suitable for people pursuing commercial opportunities.


Register


Abzena plc

RSS Portfolio

abzena-logo.png


Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products, a growing area that requires specialist knowledge and expertise. The Group has a global customer base which includes the majority of the top 20 biopharmaceutical companies as well as large and small biotech companies and academic groups.

The term "Abzena inside" is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™ and ThioBridge™ antibody drug conjugates. Abzena has the potential to earn future licence fees, milestone payments and/or royalties on "Abzena inside" products.

 

EPIC: ABZA
Market: AIM
52-week High/Low: 64.00p / 32.50p
Market Cap: 50.40M


View full company profile

Amryt Pharmaceuticals

RSS Portfolio

amryt-pharma.jpg


Amryt Pharma is a specialty pharmaceutical company focused on the developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases.

EPIC: AMYT
Market: AIM
52-week High/Low: 23.75p / 2.80p
Market Cap: 38.54M


View full company profile

Clinigen Group PLC

RSS Portfolio

clinigen-logo.png


Clinigen Group is a global pharmaceutical and services company with a unique combination of businesses focused on medicines access, delivering the right drug to the right patient at the right time.

The Group consists of five synergistic businesses;
Clinigen Clinical Trial Services is the global market leader in the management and supply of commercial medicines for clinical trials. Clinigen is also the trusted global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need; through Idis MA (Managed Access) we run early access programs for innovative new medicines; through our Idis GA (Global Access) and Link Healthcare teams we work directly with healthcare providers to enable ethical compliant access to unlicensed medicines on a global basis and local access to niche essential licensed medicines in the AAA region (Asia, Africa and Australasia). Clinigen Specialty Pharmaceuticals acquires global rights, revitalises and markets our own portfolio of niche hospital commercial products.

Clinigen is traded in the ISDX Exchange HERE

EPIC: CLIN
Market: AIM
52-week High/Low: 860.00p / 492.75p
Market Cap: 966.79M


View full company profile

Redx Pharma Plc

RSS Portfolio

redx-logo.png


Redx Pharma is a drug discovery and development company formed in 2010. It is focused on improving the characteristics of existing drug classes to create best-in-class new drugs in the areas of cancer, infection and autoimmune disease. The company's work has been endorsed by partnerships with global pharmaceutical companies and the NHS.

EPIC: REDX
Market: AIM
52-week High/Low: 67.50p / 25.00p
Market Cap: 36.54M


View full company profile
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC